Gilead seeks aztreonam lysine approval |
|
|
|
Published
:
Fri, 16 Nov 2007 20:17 |
FOSTER CITY, Calif. (AP) - Biotechnology company Gilead Sciences Inc. said Friday it has asked the Food and Drug Administration to approve its aztreonam lysine inhaled cystic fibrosis treatment.The drug is intended to be administered three times per day, at 75-milligram doses.Cystic fibrosis is a chronic, genetic disease in which thick, sticky mucus in the lungs traps bacteria, predisposing patients to lung infections.Shares of Gilead rose 74 cents to $44.37 in afternoon trading.Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
|
|
|
|